Barclays
ESPR

Barclays’s Esperion Therapeutics ESPR Stock Holding History

Barclays’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,000
Closed -$60K – 6217
2019
Q4 		$60K Sell
1,000
-1,900
-66% -$85.4K ﹤0.01% 5684
2019
Q3 		$106K Hold
2,900
– – ﹤0.01% 5436
2019
Q2 		$135K Buy
2,900
+1,800
+164% +$84.5K ﹤0.01% 5450
2019
Q1 		$44K Sell
1,100
-400
-27% -$17.9K ﹤0.01% 5965
2018
Q4 		$69K Sell
1,500
-24,200
-94% -$1.17M ﹤0.01% 5281
2018
Q3 		$1.14M Buy
25,700
+1,800
+8% +$82.6K ﹤0.01% 3501
2018
Q2 		$937K Buy
23,900
+23,500
+5,875% +$1.19M ﹤0.01% 3358
2018
Q1 		$29K Buy
400
+300
+300% +$22K ﹤0.01% 6262
2017
Q4 		$7K Hold
100
– – ﹤0.01% 6595
2017
Q3 		$5K Sell
100
-74,900
-100% -$3.61M ﹤0.01% 6404
2017
Q2 		$3.47M Buy
+75,000
New +$2.76M ﹤0.01% 1759
2015
Q3 		– Sell
-2,500
Closed -$203K – 6884
2015
Q2 		$203K Buy
+2,500
New +$245K ﹤0.01% 4133

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Barclays's ESPR Position: Q2 2026 in Review

Barclays reduced its Esperion Therapeutics (ESPR) stake by 84% in Q2 2026, selling an estimated $3.06M and leaving 207,293 shares worth $655K. The position accounts for ﹤0.01% of the portfolio, ranked #3056.

Barclays first reported a position in ESPR in Q3 2013 and has held it in 52 quarters since. The position peaked at $9.5M in Q2 2020. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Barclays held 207,293 shares of Esperion Therapeutics worth $655K as of Q2 2026.
  • Barclays sold 1,094,618 Esperion Therapeutics shares in Q2 2026, an estimated $3.06M.
  • Esperion Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3056 holding.
  • Barclays first reported a position in Esperion Therapeutics in Q3 2013 and has held it in 52 quarters since.
  • Barclays's Esperion Therapeutics position peaked at $9.5M in Q2 2020.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.